IL270986B - Botulinum neurotoxin for the treatment of disorders related to the overactivity of melanocytes and/or excess melanin - Google Patents

Botulinum neurotoxin for the treatment of disorders related to the overactivity of melanocytes and/or excess melanin

Info

Publication number
IL270986B
IL270986B IL270986A IL27098619A IL270986B IL 270986 B IL270986 B IL 270986B IL 270986 A IL270986 A IL 270986A IL 27098619 A IL27098619 A IL 27098619A IL 270986 B IL270986 B IL 270986B
Authority
IL
Israel
Prior art keywords
treatment
disorders associated
botulinum neurotoxin
excess melanin
melanocyte hyperactivity
Prior art date
Application number
IL270986A
Other languages
English (en)
Hebrew (he)
Other versions
IL270986A (en
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL270986A publication Critical patent/IL270986A/en
Publication of IL270986B publication Critical patent/IL270986B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
IL270986A 2017-05-31 2019-11-27 Botulinum neurotoxin for the treatment of disorders related to the overactivity of melanocytes and/or excess melanin IL270986B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762512792P 2017-05-31 2017-05-31
PCT/US2018/035025 WO2018222652A1 (en) 2017-05-31 2018-05-30 Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Publications (2)

Publication Number Publication Date
IL270986A IL270986A (en) 2020-01-30
IL270986B true IL270986B (en) 2021-07-29

Family

ID=62683456

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270986A IL270986B (en) 2017-05-31 2019-11-27 Botulinum neurotoxin for the treatment of disorders related to the overactivity of melanocytes and/or excess melanin

Country Status (16)

Country Link
US (3) US10912823B2 (https=)
EP (1) EP3630298A1 (https=)
JP (1) JP7096845B2 (https=)
KR (1) KR20200011499A (https=)
CN (1) CN110891594A (https=)
AU (1) AU2018277754A1 (https=)
BR (1) BR112019025402A2 (https=)
CA (1) CA3065542A1 (https=)
CL (1) CL2019003484A1 (https=)
CO (1) CO2019014592A2 (https=)
IL (1) IL270986B (https=)
MX (1) MX2019014349A (https=)
PH (1) PH12019502721A1 (https=)
RU (1) RU2019143639A (https=)
WO (1) WO2018222652A1 (https=)
ZA (1) ZA201907916B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
KR20210097530A (ko) * 2020-01-30 2021-08-09 (주)메디톡스 Snare 복합체의 형성을 저해하는 펩티드, 및 그의 용도
KR102550756B1 (ko) * 2022-12-21 2023-07-05 (주)메디톡스 세포로부터 신경전달물질 분비를 저해하는 펩티드, 및 그의 용도
CN121511091A (zh) 2023-07-12 2026-02-10 莫茨药物股份两合公司 通过肉毒杆菌毒素的色素沉着过度病况治疗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
KR20050094817A (ko) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20120195878A1 (en) * 2011-01-28 2012-08-02 Allergan, Inc. Protocol for the administration of botulinum toxins
US20140276359A1 (en) * 2013-03-15 2014-09-18 Plum Systems Co. Apparatus and method for tissue rejuvenation
AU2014301116B2 (en) * 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
CN105683212B (zh) * 2013-08-21 2020-03-17 香港理工大学 高催化活性的基因改造梭菌属神经毒素
WO2016048689A1 (en) * 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
MX2019005833A (es) * 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
AU2018389104A1 (en) * 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

Also Published As

Publication number Publication date
JP2020522492A (ja) 2020-07-30
US20210162027A1 (en) 2021-06-03
BR112019025402A2 (pt) 2020-06-23
AU2018277754A1 (en) 2020-01-02
RU2019143639A (ru) 2021-06-30
US20230302103A1 (en) 2023-09-28
PH12019502721A1 (en) 2020-10-19
KR20200011499A (ko) 2020-02-03
CL2019003484A1 (es) 2020-05-15
EP3630298A1 (en) 2020-04-08
US20180344820A1 (en) 2018-12-06
ZA201907916B (en) 2021-05-26
WO2018222652A1 (en) 2018-12-06
CO2019014592A2 (es) 2020-06-09
MX2019014349A (es) 2020-07-28
JP7096845B2 (ja) 2022-07-06
CN110891594A (zh) 2020-03-17
IL270986A (en) 2020-01-30
RU2019143639A3 (https=) 2021-09-06
CA3065542A1 (en) 2018-12-06
US10912823B2 (en) 2021-02-09

Similar Documents

Publication Publication Date Title
ZA201907916B (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
IL304429A (en) Methods and compositions for treatment of epileptic disorders
DK3673080T3 (da) Antisense-oligomerer til behandling af lidelser og sygdomme
IL258955A (en) Compositions and methods for treatment of cancer
IL268814A (en) Compositions and methods for treatment of cancer
DK3481852T5 (da) Hidtil ukendt botulinum-neurotoksin og dets derivater
DK3472455T3 (da) Kontrol- eller behandlingssystem og fremgangsmåde
PT3244819T (pt) Dispositivo para o tratamento cosmético de manchas cutâneas castanhas por criogenia
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3206686T3 (da) Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
DK3368071T3 (da) Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning
IL268688B1 (en) Improved use of botulinum toxin to treat sialorrhea
EP3471836C0 (en) DERMATOLOGICAL PREPARATIONS FOR MAINTAINING AND/OR RESTORING HEALTHY SKIN MICROBIOTA
GB201611535D0 (en) Methods and compositions for treating cancer with siglec-9 activity modulators
EP3600221A4 (en) BOTULINARY NEUROTOXINS FOR USE IN THERAPY
IL270900A (en) Treatment of cutaneous disorders
DK3532064T3 (da) Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
DK3508202T3 (da) Terapeutisk middel til amyotrofisk lateral sklerose og sammensætning til behandling
IL276930A (en) Botulinum toxin biohybrid
EP3518898C0 (en) PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY
SG11202002876WA (en) Treatment of autonomic disorders with botulinum toxin
IL264977A (en) Methods and compositions for the treatment of melanoma
DK3630112T3 (da) Kombination af regorafenib og nivolumab til behandling af cancer
IL281721A (en) Modulation of granzyme k activity in the treatment of skin conditions
ZA202002910B (en) Treatment of skin disorders